These 2 Stocks Could Be Prime Takeover Targets, According to Analysts

The company’s leading drug candidate, RMC-6236, also called daraxonrasib, made headlines recently when the company released a set of clinical trial results that support initiating the RASolute 303 global Phase 3 registrational trial of the drug as a treatment for first-line metastatic pancreatic ductal adenocarcinoma. This is a particularly dangerous form of pancreatic cancer, and existing treatments have, at best, limited efficacy.It’s not an easy approach, however. RAS mutations occur in about one-third o ...